Evaluation of Safety, Tolerability, and Pharmacokinetics of ION464 in Adult Patients with Multiple System Atrophy

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of ION464 when administered to adults diagnosed with **Multiple System Atrophy**. This is clinically relevant as it aims to determine the potential therapeutic benefits and risks associated with ION464, which could inform future treatment strategies for this progressive neurodegenerative disorder.

The clinical trial involves a total of **5 participants** diagnosed with **Multiple System Atrophy**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected based on specific criteria, although the principal inclusion criteria were not provided. The trial includes a vulnerable population, indicating that special considerations may be necessary for their participation. Lifestyle factors such as diet, physical activity, or habits were not specified. The sponsor did not provide detailed information regarding the general health status of the participants.

The clinical trial is designed to evaluate the safety, tolerability, and pharmacokinetics of a treatment administered to adults diagnosed with **Multiple System Atrophy**. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research focusing on assessing the safety profile of a new intervention. The trial employs a randomized, double-blind, and controlled design to ensure unbiased results and to maintain the integrity of the data collected. The estimated duration of the trial spans from January 15, 2020, to November 29, 2027, allowing for comprehensive data collection and analysis over several years.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. This initial visit is crucial for determining eligibility based on predefined criteria. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits. These visits are scheduled to monitor the participants' health, assess the treatment's effects, and ensure adherence to the study protocol. The end-of-study visit marks the conclusion of a participant's involvement, where final assessments are conducted to gather comprehensive data on the treatment's impact.

The expected length of participant involvement in the trial is contingent upon the study's timeline and individual response to the treatment. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with the study protocol, or withdraw consent. Such conditions are in place to prioritize participant safety and maintain the study's ethical standards. The trial's design and procedures are meticulously crafted to ensure the collection of reliable data while safeguarding the well-being of all participants involved.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the experimental medication's maximum daily dose, maximum total dose, or maximum treatment period. Furthermore, there is no information regarding whether the formulation is pediatric or if the medication is classified as an **orphan drug**.

As the source data does not provide any information about the substances used in the trial, it is not possible to describe the pharmaceutical form, product name, or any other characteristics of the investigational products. Consequently, the description remains limited to the acknowledgment of the lack of available data in the source provided.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date was January 15, 2020, with an anticipated end date of November 29, 2027. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy through various measures, which may include biomarker levels or symptom improvement scores. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but such trials generally employ validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.